137 related articles for article (PubMed ID: 31796507)
1. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
[TBL] [Abstract][Full Text] [Related]
2. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S; Asano M; Adachi Y; Matsui J
Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
[TBL] [Abstract][Full Text] [Related]
3. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
[TBL] [Abstract][Full Text] [Related]
5. The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma.
Li KK; Goodall J; Goding CR; Liao SK; Wang CH; Lin YC; Hiraga H; Nojima T; Nagashima K; Schaefer KL; Lee KA
Br J Cancer; 2003 Sep; 89(6):1072-8. PubMed ID: 12966428
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.
Davis IJ; Kim JJ; Ozsolak F; Widlund HR; Rozenblatt-Rosen O; Granter SR; Du J; Fletcher JA; Denny CT; Lessnick SL; Linehan WM; Kung AL; Fisher DE
Cancer Cell; 2006 Jun; 9(6):473-84. PubMed ID: 16766266
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
[TBL] [Abstract][Full Text] [Related]
9. Eribulin shows high concentration and long retention in xenograft tumor tissues.
Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
[TBL] [Abstract][Full Text] [Related]
11. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.
De Vita A; Miserocchi G; Recine F; Mercatali L; Pieri F; Medri L; Bongiovanni A; Cavaliere D; Liverani C; Spadazzi C; Amadori D; Ibrahim T
Molecules; 2016 Dec; 21(12):. PubMed ID: 27918490
[TBL] [Abstract][Full Text] [Related]
12. Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma.
de la Fouchardiere A; Pissaloux D; Tirode F; Hanna J
Virchows Arch; 2021 Oct; 479(4):841-846. PubMed ID: 33462743
[TBL] [Abstract][Full Text] [Related]
13. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.
Hayasaka N; Takada K; Nakamura H; Arihara Y; Kawano Y; Osuga T; Murase K; Kikuchi S; Iyama S; Emori M; Sugita S; Hasegawa T; Takasawa A; Miyanishi K; Kobune M; Kato J
Sci Rep; 2019 Apr; 9(1):5759. PubMed ID: 30962488
[TBL] [Abstract][Full Text] [Related]
14. MITF::CREM-rearranged tumor: a novel group of cutaneous tumors with melanocytic differentiation.
Kalmykova A; Mosaieby E; Kacerovská D; Baranovska-Andrigo V; Martínek P; Smahová S; Michal M; Michal M
Virchows Arch; 2023 Oct; 483(4):569-575. PubMed ID: 37550584
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.
Antonescu CR; Tschernyavsky SJ; Woodruff JM; Jungbluth AA; Brennan MF; Ladanyi M
J Mol Diagn; 2002 Feb; 4(1):44-52. PubMed ID: 11826187
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
17. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
18. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Tanaka S; Ishii T; Sato F; Toi M; Itou J
Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Yokoyama S; Feige E; Poling LL; Levy C; Widlund HR; Khaled M; Kung AL; Fisher DE
Pigment Cell Melanoma Res; 2008 Aug; 21(4):457-63. PubMed ID: 18627530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
